A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy-Reference-Cited by-同舟云学术

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy

Published:2009-07 Issue:35 Volume:27 Page:4826-4833
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Alvarez-Rueda Nidia,Ladjemi Maha Zohra,Béhar Ghislaine,Corgnac Stéphanie,Pugnière Martine,Roquet Françoise,Bascoul-Mollevi Caroline,Baty Daniel,Pèlegrin André,Navarro-Teulon Isabelle

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference40 articles.

1. Growth factor receptors and the progression of breast cancer;Kern;Semin Cancer Biol,1990

2. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer;Berchuck;Cancer Res,1990

3. Biomarker conservation in primary and metastatic epithelial ovarian cancer;Tewari;Gynecol Oncol,2000

4. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product;Fendly;Cancer Res,1990

5. HER-2/neu as a predictive marker of response to breast cancer therapy;Pegram;Breast Cancer Res Treat,1998

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2;Journal of Virology;2024-02-20

2. Anti-Idiotypic Nanobodies Mimicking an Epitope of the Needle Protein of the Chlamydial Type III Secretion System for Targeted Immune Stimulation;International Journal of Molecular Sciences;2024-02-07

3. Nanobodies Selectively Binding to the Idiotype of a Dengue Virus Neutralizing Antibody Do Not Necessarily Mimic the Viral Epitope;Biomolecules;2023-03-17

4. Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin;Molecular Cancer Therapeutics;2022-08-05

5. Mechanistic insights into the rational design of masked antibodies;mAbs;2022-07-07